amikacin + piperacillin + tazobactam

This is a combination of three antibiotics—amikacin (an aminoglycoside), piperacillin (a broad-spectrum ureidopenicillin), and tazobactam (a β-lactamase inhibitor). The combination is used primarily for the treatment of severe infections caused by multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa and extended-spectrum β-lactamase (ESBL)-producing Enterobacterales. Amikacin acts by binding to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while tazobactam protects piperacillin from degradation by β-lactamases produced by resistant bacteria. The combination has demonstrated synergistic bactericidal activity in vitro and in clinical studies, with enhanced efficacy compared to monotherapy and suppression of resistance emergence[1][2][3][5][6]. It is often considered as a carbapenem-sparing regimen for serious infections such as nosocomial pneumonia, complicated urinary tract infections, intra-abdominal infections, sepsis in neonates or immunocompromised patients[8][9].

Other names

amikacin and piperacillin/tazobactamamikacin plus piperacillin-tazobactam